The estimated Net Worth of C Frank Bennett is at least $4.69 millió dollars as of 1 February 2024. C Bennett owns over 1,853 units of Ionis Pharmaceuticals Inc stock worth over $3,363,230 and over the last 9 years he sold IONS stock worth over $372,704. In addition, he makes $958,865 as Chief Scientific Officer at Ionis Pharmaceuticals Inc.
Sign up
C Bennett IONS stock SEC Form 4 insiders trading
C has made over 30 trades of the Ionis Pharmaceuticals Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he sold 1,853 units of IONS stock worth $91,761 on 1 February 2024.
The largest trade he's ever made was exercising 22,805 units of Ionis Pharmaceuticals Inc stock on 9 November 2016 worth over $257,012. On average, C trades about 5,926 units every 51 days since 2016. As of 1 February 2024 he still owns at least 79,079 units of Ionis Pharmaceuticals Inc stock.
You can see the complete history of C Bennett stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
C. Frank Bennett biography
Dr. C. Frank Bennett Ph.D. has been appointed as Chief Scientific Officer of the Company effective 1/1/2020. From January 2006 to December 2019, Dr. Bennett served as Senior Vice President, Antisense Research. From June 1995 to January 2006, Dr. Bennett served as our Vice President, Research. From March 1993 to June 1995, he was Director, Molecular Pharmacology, and from May 1992 to March 1993, he was an Associate Director in our Molecular and Cellular Biology department. Prior to joining Ionis in 1989, Dr. Bennett was employed by SmithKline and French Laboratories in various research positions. He is an external member of the Scientific Advisory Board of Experimental Therapeutics Center in Singapore and the Hereditary Disease Foundation.
What is the salary of C Bennett?
As the Chief Scientific Officer of Ionis Pharmaceuticals Inc, the total compensation of C Bennett at Ionis Pharmaceuticals Inc is $958,865. There are 18 executives at Ionis Pharmaceuticals Inc getting paid more, with Stanley Crooke having the highest compensation of $9,598,830.
How old is C Bennett?
C Bennett is 63, he's been the Chief Scientific Officer of Ionis Pharmaceuticals Inc since 2020. There are 12 older and 13 younger executives at Ionis Pharmaceuticals Inc. The oldest executive at Ionis Pharmaceuticals Inc is Breaux Castleman, 79, who is the Independent Director.
What's C Bennett's mailing address?
C's mailing address filed with the SEC is 2855 GAZELLE COURT, , CARLSBAD, CA, 92010.
Insiders trading at Ionis Pharmaceuticals Inc
Over the last 9 years, insiders at Ionis Pharmaceuticals Inc have traded over $32,069,332 worth of Ionis Pharmaceuticals Inc stock. The most active insiders traders include Stanley T Crooke, B Lynne Parshall és Michael R Hayden. On average, Ionis Pharmaceuticals Inc executives and independent directors trade stock every 8 days with the average trade being worth of $445,289. The most recent stock trade was executed by Richard S Geary on 28 August 2024, trading 651 units of IONS stock currently worth $32,159.
What does Ionis Pharmaceuticals Inc do?
ionis pharmaceuticals, inc., located in the north san diego county city of carlsbad, was founded in 1989 to create advanced, novel medicines to treat complex and challenging diseases. we are the pioneer in the discovery and development of antisense drugs with more than 1300 patents. ionis is a challenging, motivating and rewarding environment designed to foster innovation and scientific excellence. our founding goals have changed little in over 27 years and our success is a direct result of our outstanding employees. we are interested in bringing together individuals with different skill sets into this creative environment to be part of a productive team. join us and experience our unique culture while you develop and expand your career. for more information about ionis and to apply for an open position, please visit our website: www.ionispharma.com.
What does Ionis Pharmaceuticals Inc's logo look like?
Complete history of C Bennett stock trades at Ionis Pharmaceuticals Inc
Ionis Pharmaceuticals Inc executives and stock owners
Ionis Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Stanley Crooke,
Executive Chairman of the Board of Directors -
Brett Monia,
Chief Executive Officer, Director -
Richard Geary,
Senior Vice President - Development -
Elizabeth Hougen,
Senior Vice President, Finance and Chief Financial Officer -
Patrick O'Neil,
Senior Vice President, Legal, General Counsel, Chief Compliance Officer and Corporate Secretary -
Joan Herman,
Director -
B. Lynne Parshall,
Director -
Dr. Brett P. Monia Ph.D.,
Founder, CEO & Director -
Dr. Stanley T. Crooke,
Scientific Advisor -
Joseph Klein,
Independent Director -
Joseph Wender,
Independent Director -
Spencer Berthelsen,
Independent Director -
Breaux Castleman,
Independent Director -
Frederick Muto,
Independent Director -
Michael Hayden,
Independent Director -
Joseph Loscalzo,
Independent Director -
Peter Reikes,
Independent Director -
B. Lynne Parshall Esq., J.D.,
Sr. Strategic Advisor & Director -
C. Frank Bennett,
Chief Scientific Officer -
Dr. Richard S. Geary,
Exec. VP & Chief Devel. Officer -
Elizabeth L. Hougen,
Exec. VP of Fin. & CFO -
Patrick R. O'Neil Esq.,
Chief Legal Officer, Gen. Counsel & Corp. Sec. -
Dr. Eric E. Swayze Ph.D.,
Exec. VP of Research -
D. Wade Walke,
Investor Relations -
Onaiza Cadoret-Manier,
Chief Corporate Development and Commercial Officer -
Eric Swayze,
Senior Vice President - Research -
Dr. C. Frank Bennett,
Exec. VP & Chief Scientific Officer -
Darren Gonzales,
Chief Accounting Officer & Sr. VP -
Joel Edwards,
VP of Corp. Operations -
Damien Mc Devitt,
Chief Business Officer -
Sarah Boyce,
Chief Business Officer -
Joseph Baroldi,
EVP, Chief Business Officer -
Kyle Jenne,
EVP, Chf GL Pdt Str Ofcr -
Allene M. Diaz,
Director -
Brian Birchler,
EVP, Corp and Development Ops -
Eugene Schneider,
EVP, Chf Clinical Develop Ofcr -
Michael J. Yang,
Director